Delivery Order SPE2DB20D6035-SPE2DB25FLXTK

Award Date 3/6/25
Potential Completion Date 3/7/25
Potential Value $3.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $10,440.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a prescription medication. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award, valued at $3,075.37, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $7,500.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product, with a completion date of July 3, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $7,049.14, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product, with a completion date of June 17, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $3,567.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a prescription medication. This contract award is not designated as a set-aside. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,197.56, is a delivery order for the supply of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product. The contract has an ultimate completion date of May 29, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $3,797.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product, with a completion date of May 31, 2024. This contract appears to be a delivery order and is not associated with a set-aside designation, indicating open competition. AmerisourceBergen also holds a...
This federal contract award, valued at $3,275.61, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a prescription medication, with an ultimate completion date of May 23, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical,...
This federal contract award, valued at $14,050.95, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product, with a completion date of December 13, 2024. The contract is a Firm Fixed Price Delivery Order, and it is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,165.25 firm fixed-price delivery order is for the supply of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product, with a performance period ending on June 3, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB20D6035
    Indefinite Delivery Contract
  • SPE2DB20D6035-SPE2DB25FLXTK
    Delivery Order

This federal contract award, valued at $3,788.57, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a medical product.

The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/5/25, 10:06 AM